Crinetics Pharmaceuticals, Inc. Income (Loss) from Equity Method Investments
Crinetics Pharmaceuticals, Inc. (CRNX) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-02-26
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was $0.00.
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was $0.00.
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2024-12-31 was $0.00.
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for the quarter ending 2024-09-30 was $0.00.
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2025 was $0.00.
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2024 was -$470.00K.
- Crinetics Pharmaceuticals, Inc. income (loss) from equity method investments for fiscal 2023 was -$5.20M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$470.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | -$470.00K 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | -$5.20M 10-K · filed 2026-02-26 |